Polymorphonuclear neutrophils from JAK2(V617F) positive MPD patients do not support hypercoagulability: A study with calibrated automated thrombography (CAT).

[1]  H. Coenraad Hemker,et al.  Calibrated Automated Thrombin Generation Measurement in Clotting Plasma , 2003, Pathophysiology of Haemostasis and Thrombosis.

[2]  H. Hemker,et al.  Phenotyping the haemostatic system by thrombography--potential for the estimation of thrombotic risk. , 2004, Thrombosis research.

[3]  T. Lecompte,et al.  In vitro effects of human neutrophil cathepsin G on thrombin generation: Both acceleration and decreased potential , 2010, Thrombosis and Haemostasis.

[4]  F. Rosendaal,et al.  Elevated endogenous thrombin potential is associated with an increased risk of a first deep venous thrombosis but not with the risk of recurrence , 2007, British journal of haematology.

[5]  J. García‐Pagán,et al.  Increased CD11b neutrophil expression in Budd–Chiari syndrome or portal vein thrombosis secondary to polycythaemia vera , 2004, British journal of haematology.

[6]  T. Baglin,et al.  Clinical measurement of thrombin generation by calibrated automated thrombography requires contact factor inhibition , 2004, Journal of thrombosis and haemostasis : JTH.

[7]  P. Petrides,et al.  Thrombotic complications in essential thrombocythemia (ET): clinical facts and biochemical riddles. , 2006, Blood cells, molecules & diseases.

[8]  T. Barbui,et al.  Risk of thrombosis in patients with essential thrombocythemia and polycythemia vera according to JAK2 V617F mutation status. , 2007, Haematologica.

[9]  M. Cazzola,et al.  Relation between JAK2 (V617F) mutation status, granulocyte activation, and constitutive mobilization of CD34+ cells into peripheral blood in myeloproliferative disorders. , 2006, Blood.

[10]  T. Barbui,et al.  Polymorphonuclear leukocyte activation and hemostasis in patients with essential thrombocythemia and polycythemia vera. , 2000, Blood.

[11]  M. Marchand-Arvier,et al.  Influence of polymorphonuclear leukocytes on the plasma clot formation as evaluated by thromboelastometry (ROTEM). , 2008, Thrombosis research.

[12]  T. Barbui,et al.  Leukocytosis as a major thrombotic risk factor in patients with polycythemia vera. , 2007, Blood.

[13]  A. Falanga,et al.  Leukocytosis, JAK2V617F Mutation, and Hemostasis in Myeloproliferative Disorders , 2007, Pathophysiology of Haemostasis and Thrombosis.

[14]  S. Béguin,et al.  Calibrated Automated Thrombin Generation in Frozen-Thawed Platelet-Rich Plasma to Detect Hypercoagulability , 2003, Pathophysiology of Haemostasis and Thrombosis.

[15]  C. Burgaleta,et al.  Increased CD11/CD18 Expression and Altered Metabolic Activity on Polymorphonuclear Leukocytes from Patients with Polycythemia vera and Essential Thrombocythemia , 2002, Acta Haematologica.

[16]  M. Lishner,et al.  Leukocyte function in chronic myeloproliferative disorders. , 1998, Blood cells, molecules & diseases.

[17]  T. Barbui,et al.  Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments , 2008, Haematologica.

[18]  T. Barbui,et al.  Leukocytosis and risk stratification assessment in essential thrombocythemia. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  A. Ewton,et al.  Essential thrombocythemia: a review of diagnostic and pathologic features. , 2006, Archives of pathology & laboratory medicine.

[20]  T. Barbui,et al.  Polymorphonuclear leukocyte activation and hemostasis in patients with essential thrombocythemia and polycythemia vera , 2000 .

[21]  V. Ugo,et al.  Increased circulating procoagulant activity and thrombin generation in patients with myeloproliferative neoplasms. , 2010, Thrombosis research.

[22]  M. Trossaërt,et al.  Mild hemophilia A with factor VIII assay discrepancy: using thrombin generation assay to assess the bleeding phenotype , 2008, Journal of thrombosis and haemostasis : JTH.

[23]  K. M. Fazili,et al.  Plant protease inhibitors: a defense strategy in plants , 2007 .

[24]  S. Béguin,et al.  The Calibrated Automated Thrombogram (CAT): a universal routine test for hyper- and hypocoagulability , 2002, Pathophysiology of Haemostasis and Thrombosis.

[25]  D. Caramazza,et al.  Correlation between leukocytosis and thrombosis in Philadelphia-negative chronic myeloproliferative neoplasms , 2009, Annals of Hematology.

[26]  F. Cervantes,et al.  Blood cell activation in myeloproliferative neoplasms , 2009, Haematologica.

[27]  D. Larson,et al.  Essential thrombocythemia beyond the first decade: life expectancy, long-term complication rates, and prognostic factors. , 2006, Mayo Clinic proceedings.

[28]  A. Falanga,et al.  Monitoring thrombin generation: Is addition of corn trypsin inhibitor needed? , 2009, Thrombosis and Haemostasis.

[29]  P. Giesen,et al.  Thrombin generation assessed as endogenous thrombin potential in patients with hyper- or hypo-coagulability. , 2003, Haematologica.

[30]  T. Barbui,et al.  Thrombin generation and activated protein C resistance in patients with essential thrombocythemia and polycythemia vera. , 2008, Blood.

[31]  T. Barbui,et al.  V617F JAK-2 mutation in patients with essential thrombocythemia: relation to platelet, granulocyte, and plasma hemostatic and inflammatory molecules. , 2007, Experimental hematology.

[32]  J. Samuelsson,et al.  Further studies of the defective stimulus‐response coupling for the oxidative burst in neutrophils in polycythemia vera , 1991, European journal of haematology.